Neoleukin is a biopharmaceutical company that develops de novo protein therapeutics for cancer, inflammation, and autoimmunity.

Neoleukin

Domain Not Resolving

Amazon Virginia Region

COVID-19

Blockthrough

Jonathan Drachman

Chief Medical Officer

Priti Patel

Vice President and Head of Research

Bill Arthur

VP, Legal Affairs and Intellectual Property

Leslie Aberman

Interim Chief Financial Officer

Sean Smith

Senior Director, Head of Statistical Programming

Aakar Shah

Senior Director of Translational Science

Aaron Moss

Legal

Alicia Hunsaker

Senior Director

Andrew Torres

Sr. Director, Head of Program Management at Neoleukin Therapeutics

Brianna Mbow

Martin Babler

Ryan Swanson

Principal Scientist

CEO & Founder

David Shoultz

Executive Director, COVID-19 Program

Javier Castellanos

Director of Computational Technology

Vice President & Head of Research

Greater Seattle Area Acquired Companies With Less Than $1B in Revenue

Greater Seattle Area Companies With Fewer Than 1000 Employees (Top 10K)

Biotechnology Companies With Fewer Than 1000 Employees (Top 10K)

United States Acquired Companies With Fewer Than 100 Employees (Top 10K)

Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. They are creating next generation immunotherapies using breakthrough de novo protein design technology. They use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.

Post-IPO Equity - Neoleukin Therapeutics

Venture Round - Neoleukin Therapeutics

Seattle

Washington

United States

North America

Neoleukin Therapeutics

Neoleukin Therapeutics reports Q4 results

Neurogene concludes merger deal with Neoleukin Therapeutics

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

Neoleukin Therapeutics promotes general counsel to interim CEO

Hong Kong

Asia

HTML5

Apache Server

GoDaddy

GoDaddy Premium DNS

Google Analytics

Google Maps API

jQuery

Microsoft Outlook

Google Tag Manager

Vimeo

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Neoleukin Therapeutics, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 17, 2024 5:57 AM	c0a8d08e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 17, 2024 5:57 AM	68847d07
crunchbase trigger	general	Oct 29, 2024 5:10 PM	7d023827
crunchbase profile	general	Oct 30, 2024 12:40 PM	3812ef3f
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	13dde790
peers	general	Oct 17, 2024 5:57 AM	0ce9e420
news basic	general	Oct 17, 2024 5:57 AM	be537975
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:NEOLEUKIN

Neoleukin

Last Close

3.44

18/12 21:00

Market Cap

8.20M

Beta: -

Volume Today

109.09K

Avg: -